相关实验视频
Updated: Jan 16, 2026

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.9K
来自阿尔茨海默氏症大脑的罕见生物活性陶寡合体支持模板错折和纤维细胞形成
Noé Quittot1,2, Dhanush Sivasankaran1,2, Dorothea Boeken3
1Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
bioRxiv : the preprint server for biology
|October 3, 2025
概括
研究人员确定了特定的可溶性蛋白形式,可触发阿尔茨海默病 (AD) 病理. 这些小的,化的寡合物开始错误折叠,可以形成有毒的聚合物或纤维.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 分子生物学分子生物学
背景情况:
- 超化陶聚合物,包括神经纤维状,是阿尔茨海默病 (AD) 的关键.
- 扩散性,高分子量 (HMW) 物种越来越多地被认为是生物活性,并且能够模拟错误折叠.
- 这些可溶性陶物种与纤维状形式的精确特征和结构关系在很大程度上仍未确定.
研究的目的:
- 描述生物活性,可溶性寡合物的结构和生物物理性质.
- 在体外确定寡合体结构,酸化和播种能力之间的关系.
- 调查生物活跃的tau物种对纤维或寡合体形成的模板潜力.
主要方法:
- 序列大小排除和离子交换染色学来分离HMW tau.
- 超分辨率,原子力和免疫金电子显微镜用于结构分析.
- 单分子阵列 (SIMOA) 用于检测表面酸化.
- 报告器细胞测试和实时震动诱导转换 (RT-QuIC) 测试以评估播种活动.
主要成果:
- 分离了多个生物活性子亚种,其特点是由于尺寸排除而早期化,并保留在离子交换柱上.
- 生物活性和非生物活性寡合物表现出相似的大小 (二聚体,三聚体,四聚体) 和形状.
- 寡合体上的表面酸化与播种能力有显著的相关性.
- 单个生物活性寡合物在女性分子度上诱导了播种和模板错折.
- 生物活跃的tau物种种植了带有截断的tau结构的纤维状组织,但带有全长tau的寡合体形成.
结论:
- 生物活性陶寡合体是具有特定染色学特性的可溶性陶的独特亚种.
- 酸化和寡合状态是tau播种活动的关键决定因素.
- 特定的tau寡合体的小度可以启动病态模板,根据条件导致寡合体或纤维状结构.
相关概念视频
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K
Amyloid Fibrils
6.3K
6.3K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824

